Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. AMIX
10. Z

Go back to Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
(NASDAQ: ARVN) Delayed: 7.67 --0 (-0%)
Previous Close $7.67    52 Week High $ 
Open $7.85    52 Week Low $ 
Day High $8.02    P/E N/A 
Day Low $7.52    EPS $ 
Volume 957,544       

(NASDAQ: ARVN) Delayed: 7.67 --0 (-0%)
Previous Close $7.67    52 Week High $ 
Open $7.85    52 Week Low $ 
Day High $8.02    P/E N/A 
Day Low $7.52    EPS $ 
Volume 957,544